Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer Medical Education on ReachMD

Name: Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Uploaded: 2024-05-06T04:00:00+00:00
Duration: 2 min 17 s
Description: SunRISe-2: A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus chemoradiotherapy in patients